TBK1: A potential therapeutic target in RA

Rheumatology

Volumn 51, Issue 4, 2012, Pages 588-589

  Migita, Kiyoshi ^a,b   Nakamura, Tadashi ^c,d  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; MATRIX METALLOPROTEINASE; PHOSPHOTRANSFERASE; TANK BINDING KINASE 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CELL ACTIVATION; EDITORIAL; GENE EXPRESSION; HUMAN; INNATE IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RNA BINDING; SYNOVIOCYTE; SYNOVITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; PROTEIN-SERINE-THREONINE KINASES; SYNOVIAL MEMBRANE;

EID: 84863340356     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker207     Document Type: Editorial

References (14)

1. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009;227: 221-33.
2. Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;1:102-10.
3. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007;13:460-9.
4. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008;60:805-12.
5. O'Neill LA. Primer: Toll-like receptor signaling pathways -what do rheumatologists need to know? Nat Clin Pract Rheumatol 2008;4:319-27.
6. Kyburz D, Rethage J, Seibl R et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003;48:642-50.
7. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005;26:469-76.
8. Fitzgerald KA, McWhirter SM, Faia KL et al. IKKE and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6.
9. Hammaker D, Boyle D, Firestein G. Synoviocyte innate immune responses: III. TANK-binding kinase 1 (TBK1) as a potential therapeutic target in rheumatoid arthritis. Rheumatology 2012;51: 610-8.
10. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci USA 1995; 92:11657-61.
11. Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J Biol Chem 1998;273:29210-7.
12. Lin R, Mamane Y, Hiscott J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem 2000;275:34320-7.
13. Kim TW, Staschke K, Bulek K et al. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med 2007;204:1025-36.
14. Kuhne M, Preston B, Wallace S et al. The MDX-1100, a fully human anti-CXCL10 (IP-10) antibody, is a high affinity, neutralizing antibody that has entered Phase I clinical trials for the treatment of Ulcerative Colitis (UC). J Immunol 2007;178:131-20.